Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
DALLAS and FORT WORTH, Texas, May 16, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 3:00 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
